Genetic polymorphisms of NQO1, CYP1A1 and TPMT and susceptibility to acute lymphoblastic leukemia in a Tunisian population

Molecular Biology Reports

Volumn 40, Issue 2, 2013, Pages 1307-1314

  Ouerhani, Slah ^a   Cherif, Nouha ^a   Bahri, Ikbel ^a   Safra, Ines ^a   Menif, Samia ^a   Abbes, Salem ^a  

^a PASTEUR INSTITUTE OF TUNIS   (Tunisia)

Author keywords

CYP1A1; Leukemia; NQO1; TPMT; Tunisia

Indexed keywords

CYTOCHROME P450 2A1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); THIOPURINE METHYLTRANSFERASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; BCR ABL GENE; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; CYP1A1 GENE; DOMINANT INHERITANCE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NQO1 GENE; ONCOGENE; POPULATION RESEARCH; RECESSIVE INHERITANCE; RISK ASSESSMENT; RISK FACTOR; TPMT GENE; TUNISIA;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP1A1; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOGISTIC MODELS; MALE; METHYLTRANSFERASES; MODELS, GENETIC; NAD(P)H DEHYDROGENASE (QUINONE); POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK; SEQUENCE ANALYSIS, DNA; TUNISIA; YOUNG ADULT;

EID: 84878348527     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-2174-y     Document Type: Article

References (48)

1. Stiller CA, Parkin DM (1996) Geographic and ethnic variations in the incidence of childhood cancer. Br Med Bull 52(4):682-703
2. Radich JP (2001) Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol Clin North Am 15:21-36
3. Raaschou-Nielsen O, Reynolds P (2006) Air pollution and childhood cancer: a review of the epidemiological literature. Int J Cancer 118(12):2920-2929
4. Belson M, Kingsley B, Holmes A (2007) Risk factors for acute leukemia in children: a review. Environ Health Perspect 115:138-145
5. Linabery AM, Ross JA (2008) Trends in childhood cancer incidence in the U.S. (1992-2004). Cancer 112(2):416-432
6. Balta G, Yuksek N, Ozyurek E et al (2003) Characterization of MTHFR, GSTM1, GSTT1, GSTP1, and CYP1A1 genotypes in childhood acute leukemia. Am J Hematol 73(3):154-160
7. Canalle R, Burim RV, Tone LG et al (2004) Genetic polymorphisms and susceptibility to childhood acute lymphoblastic leukemia. Environ Mol Mutagen 43(2):100-109
8. Lanciotti M, Dufour C, Corral L et al (2005) Genetic polymorphism of NAD(P)H:quinone oxidoreductase is associated with an increased risk of infant acute lymphoblastic leukemia without MLL gene rearrangements. Leukemia 19(2):214-216
9. Smith MT, Wang Y, Kane E et al (2001) Low NAD(P)H:quinone oxidoreductase 1 activity is associated with increased risk of acute leukemia in adults. Blood 97:1422-1426
10. Samochatova EV, Chupova NV, Rudneva A (2009) TPMT genetic variations in populations of the Russian Federation. Pediatr Blood Cancer 52(2):203-208
11. Ingelman-Sundberg M (2001) Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat Res 482:11-19
12. Long DJ II, Waikel RL, Wang XJ et al (2000) NAD(P)H:quinine oxidoreductase 1 deficiency increases susceptibility to benzo(a)pyrene-induced mouse skin carcinogenesis. Cancer Res 60:5913-5915
13. Long DJ II, Waikel RL, Wang XJ et al (2001) NAD(P)H:quinine oxidoreductase 1 deficiency and increased susceptibility to 7,12-dimethylbenz[a] -anthracene-induced carcinogenesis in mouse skin. J Natl Cancer Inst 93:1166-1170
14. De Flora S, Bennicelli C, D'Agostini F et al (1994) Cytosolic activation of aromatic and heterocyclic amines. Inhibition by dicoumarol and enhancement in viral hepatitis B. Environ Health Perspect 102(Suppl 6):69-74
15. Knox ChenS, Lewis AD et al (1995) Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: study involving mouse, human, and mouse-rat chimeric enzymes. Mol Pharmacol 47:934-936
16. Iida A, Sekine A, Saito S et al (2001) Catalog of 320 single nucleotide polymorphisms (SNPs) in 20 quinone oxidoreductase and sulfotransferase genes. J Hum Genet 46:225-240
17. Hamajima N, Matsuo K, Iwata H et al (2002) NAD(P)H: quinone oxidoreductase 1 (NQO1) C609T polymorphism and the risk of eight cancers for Japanese. Int J Clin Oncol 7:103-108
18. Krajinovic M, Sinnett H, Richer C et al (2002) Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Int J Cancer 97(2):230-236
19. Gaedigk A, Tyndale RF, Jurima-Romet M et al (1998) NAD(P)H: quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. Pharmacogenetics 8(4):305-313
20. Schutz E, Gummert J, Mohr F et al (1993) Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet 341:436
21. Kerstens PJ, Stolk JN, de Abreu R et al (1995) Azathioprine-related bone marrow toxicity and low activities of purine enzymes in patients with rheumatoid arthritis. Arthritis Rheum 38:142-145
22. McLeod HL, Relling MV, Liu Q et al (1995) Polymorphic thiopurine methyltransferase in erythrocytes is indicative of activity in leukemic blasts from children with acute lymphoblastic leukemia. Blood 85:1897-1902
23. Salavaggione OE, Wang L, Wiepert M et al (2005) Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet Genomics 15:801-815
24. Schaeffeler E, Zanger UM, Eichelbaum M et al (2008) Highly multiplexed genotyping of thiopurine s-methyltransferase variants using MALD-TOF mass spectrometry: reliable genotyping in different ethnic groups. Clin Chem 54:1637-1647
25. McLeod HL, Krynetski EY, Relling MV et al (2000) Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 14:567-572
26. Otterness D, Szumlanski C, Lennard L et al (1997) Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 62:60-73
27. Hon YY, Fessing MY, Pui CH et al (1999) Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet 8:371-376
28. Collie-Duguid ESR, Pritchard SC, Powrie RH et al (1999) The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 9:37-42
29. Menif S, Zarrouki S, Jeddi R et al (2009) Quantitative detection of bcr-abl transcripts in chronic myeloid leukemia. Pathol Biol 57(5):388-391
30. Kelsey KT, Ross D, Traver RD et al (1997) Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer 76(7):852-854
31. Reddy P, Naidoo RN, Robins TG et al (2010) GSTM1, GSTP1, and NQO1 polymorphisms and susceptibility to atopy and airway hyperresponsiveness among South African schoolchildren. Lung 188(5):409-414
32. Guha N, Chang JS, Chokkalingam AP et al (2008) NQO1 polymorphisms and de novo childhood leukemia: a HuGE review and meta-analysis. Am J Epidemiol 168(11):1221-1320
33. Ross D, Kepa JK, Winski SL et al (2000) NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem Biol Interact 129(1-2):77-97
34. Vijayakrishnan J, Houlston RS (2010) Candidate gene association studies and risk of childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Haematologica 95(8):1405-1414
35. Ernester L (1998) DT-diaphorase: its structure, function, regulation, and role in antioxidant defence and cancer chemotherapy. In: Yagi K (ed) Pathophysiology of lipid peroxides and related free radicals. S Karger, Basel, pp 149-168
36. Ross D (1997) Quinone reductases. In: Guengerich FP (ed) Comprehensive toxicology, vol 3. Pergamon Press, New York, pp 179-197
37. Asher G, Lotem J, Kama R et al (2002) NQO1 stabilizes p53 through a distinct pathway. Proc Natl Acad Sci USA 99:3099-3104
38. Anwar A, Dehn D, Siegel D et al (2003) Interaction of human NAD(P)H:quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems. J Biol Chem 278:10368-10373
39. Rimando MG, Chua MN, Yuson ED et al (2008) Prevalence of GSTT1, GSTM1 and NQO1 (609C>T) in Filipino children with ALL (acute lymphoblastic leukaemia). Biosci Rep 28(3):117-124
40. Kracht T, Schrappe M, Strehl S et al (2004) NQO1 C609T polymorphism in distinct entities of pediatric hematologic neoplasms. Haematologica 89(12):1492-1497
41. Wiemels JL, Pagnamenta A, Taylor GM et al (1999) A lack of a functional NAD(P)H: quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom Childhood Cancer Study Investigators. Cancer Res 59:4095-4099
42. Liu QX, Chen HC, Liu XF et al (2005) Study on the relationship between polymorphisms of CYP1A1, GSTM1, GSTT1 genes and the susceptibility to acute leukemia in the general population of Hunan province. Zhonghua Liu Xing Bing Xue Za Zh 26(12):975-979
43. Krajinovic M, Labuda D, Richer C et al (1999) Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood 93(5):1496-1501
44. Clavel J, Bellec S, Rebouissou S et al (2005) Childhood leukaemia, polymorphisms of metabolism enzyme genes, and interactions with maternal tobacco, coffee and alcohol consumption during pregnancy. Eur J Cancer Prev 14(6):531-540
45. Ameyaw MM, Collie-Duguid ES, Powrie RH et al (1999) Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet 8(2):367-370
46. Spire-Vayron de la Moureyre C, Debuysere H, Mastain B et al (1998) Genotypic and phenotypic analysis of the polymorphic thiopurine S-methyltransferase gene (TPMT) in a European population. Br J Pharmacol 125:879-887
47. Yates CR, Krynetski EY, Fessing MY et al (1997) Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 126:608-614
48. Relling MV, Hancock ML, Rivera GK et al (1999) Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 91:2001-2008